Press Releases

Jul 8, 2022

Jnana Therapeutics to Present Preclinical Data for its PKU Program at the 2022 National PKU Alliance (NPKUA) Conference

BOSTON, Mass., July 8, 2022 – Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for highly validated, previously undruggable targets to treat diseases with high unmet need, will present preclinical data for its lead program, a potential first-in-class oral approach for the treatment of phenylketonuria (PKU). Data will be presented […]

Read More >

Apr 26, 2022

Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer

BOSTON, Mass., April 26, 2022 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to address well-validated but hard-to-drug targets, today announced the appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Pagán will be responsible for spearheading the company’s finance, operations and IT functions, including capital […]

Read More >


Aug 18, 2021

Jnana closes $50M series B round, picks PKU as lead indication


Aug 18, 2021

Jnana nets $50M to push newly unveiled PKU program, expand into more hard-to-drug targets

Fierce Biotech

Oct 12, 2020

Fragment-based screening sees the light

Nature Reviews Drug Discovery, October 2020

Jul 22, 2020

Roche, Jnana sign multi-target collaboration deal for small molecule drugs

Pharmaceutical Business Review

Jul 21, 2020

Roche, Jnana Enter Drug R&D Alliance Targeting Metabolism’s Gatekeepers


Jul 21, 2020

Roche, Jnana take aim at metabolite transporters in $40M discovery deal

Fierce Biotech

Apr 16, 2020

Scripps Research expands international effort to rapidly repurpose existing drugs against COVID-19

Scripps Research, April 2020

Oct 14, 2018

Jnana Therapeutics tries to take on an untapped class of proteins

Chemical and Engineering News, October 2018


Back to Top

This links to an external website. Merus is not responsible for any third party content.